{"filings":[{"id":103166,"accession_number":"0001753926-26-000577","cik":1347242,"company_name":"LIPELLA PHARMACEUTICALS INC.","ticker":"LIPO","form_type":"8-K","filed_at":"2026-03-31T23:59:59+00:00","items":["1.03","9.01"],"status":"ready","headline":"Lipella Pharmaceuticals files Chapter 11 bankruptcy, plans 363 sale process","event_type":"other_material","confidence":"high","bullets":["Filed voluntary Chapter 11 petition in Western District of Pennsylvania on March 30, 2026.","Company intends to pursue a 363 sale process to maximize value for creditors.","Seeks customary first-day relief to continue operations, including payroll and cash management.","Company cautions trading in common stock is highly speculative and may not reflect recovery for holders."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":1.0,"daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":103165,"accession_number":"0001753926-26-000265","cik":1347242,"company_name":"LIPELLA PHARMACEUTICALS INC.","ticker":"LIPO","form_type":"8-K","filed_at":"2026-02-04T23:59:59+00:00","items":["5.02"],"status":"ready","headline":"Lipella board member Lori A. Birder resigns effective February 3, 2026","event_type":"leadership","confidence":"high","bullets":["Lori A. Birder resigned from Lipella Pharmaceuticals' Board of Directors, effective immediately on February 3, 2026.","Resignation not due to any disagreement with the company on operations, policies or practices.","No replacement director has been announced as of the filing date."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.25,"daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":119404,"accession_number":"0001753926-25-001636","cik":1347242,"company_name":"LIPELLA PHARMACEUTICALS INC.","ticker":"LIPO","form_type":"8-K","filed_at":"2025-10-21T23:59:59+00:00","items":["5.02"],"status":"ready","headline":"Director Naoki Yoshimura to retire from Lipella board effective Dec 31, 2025","event_type":"leadership","confidence":"high","bullets":["Naoki Yoshimura notified Lipella of his intention to retire from the Board of Directors, effective December 31, 2025.","The retirement is not the result of any disagreement with the company regarding operations, policies, or practices.","No replacement for the departing director has been announced as of the filing date."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.35,"daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":119403,"accession_number":"0001753926-25-001602","cik":1347242,"company_name":"LIPELLA PHARMACEUTICALS INC.","ticker":"LIPO","form_type":"8-K","filed_at":"2025-10-09T23:59:59+00:00","items":["5.02"],"status":"ready","headline":"Lipella Pharmaceuticals CMO and Board Member Michael Chancellor to retire effective Dec 4, 2025","event_type":"leadership","confidence":"high","bullets":["Dr. Michael Chancellor notified intention to retire as Chief Medical Officer and Board member.","Retirement effective December 4, 2025; no disagreement with company cited.","Dr. Chancellor's departure planned and not due to policy or operational disputes."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.4,"daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":135954,"accession_number":"0001753926-25-001525","cik":1347242,"company_name":"LIPELLA PHARMACEUTICALS INC.","ticker":"LIPO","form_type":"8-K","filed_at":"2025-09-18T23:59:59+00:00","items":["7.01","8.01","9.01"],"status":"ready","headline":"Lipella reports positive Phase 2a results for LP-10 in oral lichen planus; all efficacy endpoints met","event_type":"other_material","confidence":"high","bullets":["All 27 patients completed 4-week treatment; no serious adverse events reported.","76% of tacrolimus blood measurements undetectable (<1.0 ng/mL); dry mouth in 18.5%.","Statistically significant improvements (p<0.05) in IGA, REU, pain, sensitivity, and OLPSSM at week 4.","Company advancing LP-10 into Phase 2b; preparing protocol with FDA feedback."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.85,"daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":152985,"accession_number":"0001753926-25-001003","cik":1347242,"company_name":"LIPELLA PHARMACEUTICALS INC.","ticker":"LIPO","form_type":"8-K","filed_at":"2025-06-25T23:59:59+00:00","items":["7.01","8.01","9.01"],"status":"ready","headline":"Lipella Pharmaceuticals Delisted from Nasdaq, Plans to Relist on National Exchange","event_type":"regulatory","confidence":"high","bullets":["Delisted from Nasdaq effective June 19, 2025 due to non-compliance with Listing Rules 5100, 5635, and 5640 regarding private placement transactions.","Common stock now quoted on OTC Pink Market under symbol LIPO; company remains fully reporting with SEC.","CEO Jonathan Kaufman issued stockholder letter detailing plans to submit initial listing application to another national exchange.","Clinical programs LP-310 (oral lichen planus) and LP-10 (hemorrhagic cystitis) continue unaffected; final LP-310 Phase 2a data expected H2 2025.","Company states delisting was not due to financial instability and maintains sufficient capital for development programs."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.8,"daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":152984,"accession_number":"0001753926-25-000984","cik":1347242,"company_name":"LIPELLA PHARMACEUTICALS INC.","ticker":"LIPO","form_type":"8-K","filed_at":"2025-06-20T23:59:59+00:00","items":["3.01","7.01","9.01"],"status":"ready","headline":"Lipella Pharmaceuticals receives Nasdaq delisting; stock moves to OTC Markets","event_type":"regulatory","confidence":"high","bullets":["Nasdaq Hearings Panel determined to delist Lipella common stock effective June 20, 2025; trading suspended.","Non-compliance with Listing Rules 5635(d) and 5640 due to Series C preferred and warrants issued in Dec 2024-Mar 2025 private placements.","Common stock now quoted on OTC Markets under symbol LIPO; company exploring other listing venues.","Company disappointed, states business fundamentals intact; continuing clinical development of LP-10 and LP-310.","Lipella remains an SEC reporting company and will continue filing periodic reports."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":1.0,"daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":152983,"accession_number":"0001753926-25-000962","cik":1347242,"company_name":"LIPELLA PHARMACEUTICALS INC.","ticker":"LIPO","form_type":"8-K","filed_at":"2025-06-16T23:59:59+00:00","items":["8.01"],"status":"ready","headline":"Lipella sets 2025 annual meeting for July 21; record date June 18","event_type":"other","confidence":"high","bullets":["2025 annual meeting scheduled for July 21, 2025; record date for voting is June 18, 2025.","Stockholder proposals for inclusion in proxy must be received by June 18, 2025.","Deadline for director nominations and other business under advance notice bylaw is June 20, 2025.","Meeting date moved more than 30 days from 2024 annual meeting (Sept 10, 2024); change disclosed per Rule 14a-5(f)."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.05,"daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":152982,"accession_number":"0001753926-25-000856","cik":1347242,"company_name":"LIPELLA PHARMACEUTICALS INC.","ticker":"LIPO","form_type":"8-K","filed_at":"2025-05-16T23:59:59+00:00","items":["3.01"],"status":"ready","headline":"Lipella receives Nasdaq deficiency notice for preferred stock issuance; faces potential delisting","event_type":"regulatory","confidence":"high","bullets":["Nasdaq notified Lipella that its Series C Preferred Stock and Warrant issuances violated Listing Rules 5635(d) and 5640 (shareholder approval and voting rights).","Issuances to investment bank between Dec 2024 and Mar 2025 involved >20% of outstanding shares at a discount to Minimum Price.","Company must respond to Nasdaq Hearings Panel by May 19, 2025; plans to seek shareholder approval and pause conversions/exercises.","No immediate effect on listing of common stock (NASDAQ: LIPO); trading continues pending Panel decision.","No assurance that Lipella will regain compliance or maintain listing; risk of delisting if not successful."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.7,"daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":152981,"accession_number":"0001753926-25-000842","cik":1347242,"company_name":"LIPELLA PHARMACEUTICALS INC.","ticker":"LIPO","form_type":"8-K","filed_at":"2025-05-15T23:59:59+00:00","items":["7.01","8.01","9.01"],"status":"ready","headline":"Lipella presents positive Phase 2a data for LP-310; 0.50mg dose shows stat-sig efficacy in OLP","event_type":"other_material","confidence":"high","bullets":["Statistically significant improvements at 0.50mg dose: IGA from 3.42 to 1.71 (p=0.007), REU from 26.91 to 11.88 (p=0.003).","OLP Symptom Severity Measure dropped from 14.92 to 4.88 (p=0.003); Pain NRS from 6.42 to 2.25 (p=0.003).","No treatment-related serious adverse events, no discontinuations, and no detectable systemic tacrolimus levels.","Data from 0.25mg and 0.50mg cohorts presented at 2025 AAOM/EAOM meeting; final topline data from fully enrolled trial expected Q2 2025."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.75,"daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":152980,"accession_number":"0001753926-25-000623","cik":1347242,"company_name":"LIPELLA PHARMACEUTICALS INC.","ticker":"LIPO","form_type":"8-K","filed_at":"2025-04-14T23:59:59+00:00","items":["8.01"],"status":"ready","headline":"Lipella Pharmaceuticals regains Nasdaq equity compliance after $5.9M placement","event_type":"other_material","confidence":"high","bullets":["Final closing of Series B convertible preferred stock offering on March 12, 2025; net proceeds ~$5.9M.","Also issued warrants to purchase up to 72,000 Series B shares at $100/share on March 17, 2025; gross proceeds $9,000.","Stockholders' equity was ~$1.9M as of Dec 31, 2024; after offerings, company believes it meets Nasdaq's Stockholders' Equity Requirement.","Nasdaq continued listing is subject to compliance; company states it currently remains in compliance."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.75,"daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":152979,"accession_number":"0001753926-25-000604","cik":1347242,"company_name":"LIPELLA PHARMACEUTICALS INC.","ticker":"LIPO","form_type":"8-K","filed_at":"2025-04-09T23:59:59+00:00","items":["5.03","3.03","9.01"],"status":"ready","headline":"Lipella increases designated Series C preferred shares from 1,050,000 to 1,260,000","event_type":"other_material","confidence":"high","bullets":["Filed Certificate of Amendment on April 8, 2025, increasing Series C Voting Convertible Preferred Stock designation from 1,050,000 to 1,260,000 shares.","Amendment modifies existing Certificate of Designation, potentially altering voting or conversion rights of current holders.","Change in authorized shares may indicate future financing or strategic moves by the company."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.4,"daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":152978,"accession_number":"0001753926-25-000585","cik":1347242,"company_name":"LIPELLA PHARMACEUTICALS INC.","ticker":"LIPO","form_type":"8-K","filed_at":"2025-04-07T23:59:59+00:00","items":["1.01","9.01"],"status":"ready","headline":"Lipella Pharma enters $2.64M ATM equity facility with H.C. Wainwright","event_type":"other_material","confidence":"high","bullets":["ATM agreement for up to $2,641,881 of common stock at market prices.","H.C. Wainwright receives 3.0% cash commission on gross proceeds.","Proceeds will be used for working capital and general corporate purposes.","Shares offered under existing effective S-3 shelf registration.","No obligation to sell; company may suspend or terminate at any time."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.6,"daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":171771,"accession_number":"0001753926-25-000467","cik":1347242,"company_name":"LIPELLA PHARMACEUTICALS INC.","ticker":"LIPO","form_type":"8-K","filed_at":"2025-03-18T23:59:59+00:00","items":["1.01","3.02","9.01"],"status":"ready","headline":"Lipella completes final close of Series B offering ($88.5K) and launches March warrant offering","event_type":"other_material","confidence":"high","bullets":["Final close sold 885 shares of Series B preferred at $100/share for $88,500 gross; net proceeds $73,455.","Warrant offering: up to 60,000 warrants at $0.125 each, each exercisable for 1 Series B share ($100) convertible at $2.16.","Placement agent Spartan receives $15,045 fees, 10,326 Series C preferred shares, and warrants for 4,060 common shares.","Registration rights require filing within 30 days; failure triggers 100,000 common shares or cash penalty monthly.","Proceeds from both offerings intended for working capital and general corporate purposes."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.65,"daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":171770,"accession_number":"0001753926-25-000425","cik":1347242,"company_name":"LIPELLA PHARMACEUTICALS INC.","ticker":"LIPO","form_type":"8-K","filed_at":"2025-03-11T23:59:59+00:00","items":["1.01","3.02","9.01"],"status":"ready","headline":"Lipella raises $726k in fourth closing of Series B preferred offering at $2.51 conversion","event_type":"other_material","confidence":"high","bullets":["Gross proceeds of $726,000 from sale of 7,260 Series B shares convertible into 289,241 common shares at $2.51/share.","Net proceeds of $602,580; Spartan Capital received $123,420 in fees, 84,700 Series C voting preferred shares and warrants for 28,924 common shares.","CEO Jonathan Kaufman granted irrevocable voting power over Spartan's issued shares via proxy.","Proceeds from the offering to be used for working capital and general corporate purposes."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.5,"daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":171769,"accession_number":"0001753926-25-000381","cik":1347242,"company_name":"LIPELLA PHARMACEUTICALS INC.","ticker":"LIPO","form_type":"8-K","filed_at":"2025-03-03T23:59:59+00:00","items":["1.01","3.02","9.01"],"status":"ready","headline":"Lipella raises $3.79M in third closing of Series B convertible preferred offering","event_type":"other_material","confidence":"high","bullets":["Sold 37,880 Series B convertible preferred shares at $100 each; gross proceeds $3.788M, net $3.124M after fees.","Over-allotment partially exercised; $385,500 from over-allotment included in gross proceeds.","Conversion price set at $3.00 or $3.13 per common share, subject to adjustment.","Spartan Capital earned $663,960 in fees, received 441,933 Series C shares and warrants for 125,833 common shares.","Second amendment makes Spartan's cash and stock compensation pro rata on total $7.2M across both offerings."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.6,"daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":171768,"accession_number":"0001753926-25-000276","cik":1347242,"company_name":"LIPELLA PHARMACEUTICALS INC.","ticker":"LIPO","form_type":"8-K","filed_at":"2025-02-24T23:59:59+00:00","items":["1.01","9.01"],"status":"ready","headline":"Lipella Pharmaceuticals amends placement agent agreement with Spartan Capital Securities","event_type":"m_and_a","confidence":"high","bullets":["Second Amendment removes at-the-market facility restrictions and modifies tail provision to require 10% fee on investments from accredited retail investors within one year of termination.","Mirror Offering capacity increased to $7,200,000 (including $1,200,000 over-allotment) with registration statements due within 30 days of closings.","Variable Rate Transaction restrictions reduced to 90 days post-termination or 10 business days after Registration Statement effective date if $6,000,000 of shares sold.","Company restricted from disposing securities for 90 days after third closing if all shares under that closing are not registered."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.6,"daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null}],"next_cursor":null}